• neues 52 Wochen-Tief
  
• weit entfernt von irgendwelchen Analysten Kurszielen
  

• neues 52 Wochen-Tief
  

https://seekingalpha.com/article/...conference-presentation-slideshow

plant 60 Mio. $ Offering

https://seekingalpha.com/news/...ock-offering-shares-12-percent-hours

Details des Offerings

• 26,66 Mio. Aktien zu je 2,25 $
  
• Volumen ~60 Mio. $
  

https://seekingalpha.com/news/...s-therapeutics-prices-stock-offering

positive Phase3 SER-109 Studienergebnisse

https://ir.serestherapeutics.com/news-releases/...ine-results-ser-109

Phase 2b ECO-RESET Studie von SER-287 (UC) verfehlt den primären Endpunkt

https://ir.serestherapeutics.com/news-releases/...ts-ser-287-phase-2b

Trotz des Phase2 Flops von SER-287 sollte man Seres nicht abschreiben. Mit SER-109 haben sie noch ein heißes Eisen im Feuer und werden voraussichtlichtlich demnächst einen Zulasungsantrag stellen. Neben den 175 Mio. $ Vorabzahlung von Nestle könnten bei Zulassung nochmal 125 Mio. $ hinzukommen und umsatzbezogene Meilensteinzahlungen bis zu 225 Mio. $.
https://www.fiercebiotech.com/biotech/...o-as-shares-go-into-freefall

https://www.fool.com/investing/2021/07/22/...stock-is-crashing-today/
https://www.fiercebiotech.com/biotech/...r-rights-to-c-diff-treatment

Zahlen für Q1/21

• Umsatz 6 Mio. $
  
• Verlust 35 Mio. $
  
• Cash 273 Mio. $
  
• MK 651 Mio. $
  

"Following successful SER-109 Phase 3 pivotal results in patients with recurrent C. difficile infection, we continue to enroll an open label study to expand our safety database. We are very pleased with the pace of study enrollment and we anticipate achieving target enrollment during the third quarter of 2021. Completion of the required SER-109 safety database will support a Biologics License Application (BLA) filing, and potentially pave the way for SER-109 to become the first-ever FDA-approved microbiome therapeutic.”

https://ir.serestherapeutics.com/news-releases/...1-financial-results

Zahlen für Q2/21

• Umsatz 5 Mio. $
  
• Verlust 48 Mio. $
  
• Cash 229 Mio. $
  
  • +175 Mio. Upfront von Nestlé vom 01. Juli
    
• MK 644 Mio. $
  

– SER-109 open-label study in patients with recurrent C. difficile infection on track to achieve enrollment target in late Q3 2021 –

– SER-109 co-commercialization agreement with Nestlé Health Science provides $310 million in upfront and contingent approval milestones, additional $225 million in contingent sales milestones, and future payments equal to 50% of profits –

https://ir.serestherapeutics.com/news-releases/...1-financial-results